Publications
Talk to Our Care TeamTali-cel is a safe and effective therapy in patients with Relapsed/Refractory Bcell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
Poster
Dec 8, 2025American Society of Hematology Meeting
A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA-directed CAR-T cell therapy.
Poster
Dec 7, 2025American Society of Hematology Meeting
A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA-directed CAR-T cell therapy.
Abstract
Nov 3, 2025American Society of Hematology Meeting
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India
Abstract
Nov 3, 2025American Society of Hematology Meeting
Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access
Abstract
Nov 3, 2025American Society of Hematology Meeting
Real World Data of the safety and efficacy of Talicabtagene Autoleucel (Humanized CD19 CAR-T) in relapsed / refractory B-cell acute lymphoblastic leukemia from India.
Poster
Jun 12, 2025European Hematology Association Congress
Safety And Efficacy Of Polatuzumab Vedotln Plus Glontamab As Bridging Therapy Prior To Talicabtagene Autoleucel For Relapsed/Refractory B-cell Lymphoma
Poster
Jun 12, 2025European Hematology Association Congress
Bridging The Gap: Inotuzumab Integration Prior To Talicabtagene Autoleucel In R/R B-ALL
Poster
Jun 12, 2025European Hematology Association Congress
Development of equitable access model for nationwide implementation of affordable CAR-T cell therapy in India a real-world experience
Poster
May 10, 2025International Society for Cell and Gene Therapy
Development of equitable access model for nationwide implementation of affordable CAR-T cell therapy in India: a real-world experience.
Article
May 10, 2025Cytotherapy
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study
Article
Apr 24, 2025Blood Cancer Journal
Talicabtagene Autoleucel for Relapsed or Refractory B-cell Malignancies: Results from an Open-label, Multicentre, Phase 1/2 Study
Article
Apr 1, 2025The Lancent Haematology
Real world data of novel Talicabtagene autoleucel (humanized CD19 CAR-T) from India; ensuring equitable access with excellent safety and efficacy profile
Poster
Dec 7, 2024American Society of Hematology Meeting
Real world data of novel Talicabtagene autoleucel (humanized CD19 CAR-T) from India; ensuring equitable access with excellent safety and efficacy profile
Abstract
Nov 5, 2024American Society of Hematology Meeting
Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies
Poster
Dec 7, 2024American Society of Hematology Meeting
Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies
Abstract
Nov 5, 2024American Society of Hematology Meeting
High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial
Poster
Dec 9, 2023American Society of Hematology Meeting
High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial
Abstract
Nov 2, 2023American Society of Hematology Meeting
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Poster
Dec 9, 2023American Society of Hematology Meeting
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Abstract
Nov 2, 2023American Society of Hematology Meeting